Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Completed 3

Sponsor Class

OTHER 8INDUSTRY 3

Study Type

Interventional 2Observational 1

Sponsor

Cancer Type

Classical hematology 3

Conditions

Venous Thromboembolism 3Venous Thrombosis 1Thromboembolism 1Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Carcinoma, Pancreatic Ductal 1Abdominal Neoplasms 1

Interventions

apixaban 5Rivaroxaban 5Dalteparin 4Enoxaparin 3edoxaban 2abelacimab 2Tinzaparin 2MAA868 2Heparin, Low-Molecular-Weight 2Dabigatran 2isoquercitrin 1calcium heparin 1betrixaban 1bemiparin 1Warfarin 1Heparin 1Gemcitabine 1Fondaparinux 1AVE 5026 1ALT-836 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Venous Thromboembolism × Enoxaparin × Clear all
NCT01583218 2023-08-07

APEX

Alexion Pharmaceuticals, Inc.

Phase 3 Completed
7,513 enrolled 18 charts 1 FDA
Classical hematology

Venous Thromboembolism

NCT01444612 2017-05-16

Comparative Analysis of Injectable Anticoagulants for Thromboprophylaxis Post Cancer-related Surgery

GlaxoSmithKline

Completed
4,068 enrolled
Classical hematology

Venous Thrombosis, Venous Thromboembolism

NCT00723216 2010-04-05

Japanese Efficacy and Safety Study of Enoxaparin in Patients With Curative Abdominal Cancer Surgery

Sanofi

Phase 3 Completed
151 enrolled
Classical hematology

Abdominal Neoplasms, Venous Thromboembolism

Data powered by HemOnc (CC BY 4.0) Colophon âš¡